Indian Journal of Dermatology
RESIDENT«SQ»S PAGE
Year
: 2017  |  Volume : 62  |  Issue : 4  |  Page : 418--421

Itolizumab in psoriasis


Ankita Srivastava 
 Department of Skin and VD, JNU Institute for Medical Sciences and Research Centre, Jaipur, Rajasthan, India

Correspondence Address:
Ankita Srivastava
Department of Skin and VD, JNU Institute for Medical Sciences and Research Centre, Jaipur, Rajasthan
India

A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with infusion reactions as the most common adverse effect. However, its advantages and disadvantages over other biologicals and immunosuppressants need to be established. Also, its utility in treating other immune-mediated disorders is being explored.


How to cite this article:
Srivastava A. Itolizumab in psoriasis.Indian J Dermatol 2017;62:418-421


How to cite this URL:
Srivastava A. Itolizumab in psoriasis. Indian J Dermatol [serial online] 2017 [cited 2020 Oct 27 ];62:418-421
Available from: https://www.e-ijd.org/article.asp?issn=0019-5154;year=2017;volume=62;issue=4;spage=418;epage=421;aulast=Srivastava;type=0